Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. My name is Tom, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amelix Pharmaceuticals second quarter 2023 earnings conference call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, please press star, then 1 on your telephone keypad. And to withdraw yourself from the question queue, please press star, then 2. Please be advised that this call is being recorded at the company's request. I would now like to turn the conference over to Lindsay Allen, Head of Investor Relations and Communications. Please go ahead. Good afternoon, and thank you for joining us today to discuss our second quarter 2023 earnings. With me on the call are Josh Cohen and Justin Klee, our co-CEOs, Margaret Olinger, our Chief Commercial Officer, and Jim Friedes, our Chief Financial Officer. Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are made based on our current beliefs, plans, and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our expectations with respect to Livrio and Albreoza, statements regarding our clinical trials and regulatory developments and the expected timing thereof, our business strategy and outlook, and our expected financial performance. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors. including those set forth in our most recent filings...